Is it the Right Time to Retain Abbott Stock in Your Portfolio?

Abbott (ABT) is demonstrating robust growth across its key segments, driven by strong adult nutrition demand, 19.6% organic growth in its FreeStyle Libre-led Diabetes Care business (bolstered by new OTC CGM approvals), and 7.7% organic growth in its Established Pharmaceuticals division with a strategic focus on biosimilars in emerging markets. While the company's stock has rallied 17.5% over the past year, outperforming its industry, it faces headwinds from macroeconomic challenges impacting expenses and demand, alongside adverse foreign currency fluctuations that negatively affected H1 2025 sales by 1.1%. Despite these pressures, 2025 earnings estimates remain stable, reflecting underlying business strength.

Analysis

Abbott Laboratories (ABT) is demonstrating robust operational momentum, with its stock rally of 17.5% over the past year significantly outperforming the broader medical device industry's 0.3% decline. This strength is primarily driven by its Diabetes Care division, where the FreeStyle Libre continuous glucose monitoring (CGM) system propelled sales to over $1.9 billion in Q2 2025, marking 19.6% organic growth. The recent FDA approvals for over-the-counter CGM systems, Lingo and Libre Rio, signal a major expansion of Abbott's addressable market beyond traditional diabetes patients. Further growth is supported by the Established Pharmaceuticals Division (EPD), which grew 7.7% organically in the quarter and is strategically positioned for long-term expansion through its biosimilar pipeline, with launches anticipated in 2026. The Nutrition segment is also recovering, led by a 6.6% organic increase in Adult Nutrition sales. These positive fundamentals are tempered by significant headwinds, including macroeconomic pressures that elevate operating expenses and a strong U.S. dollar, which created a 1.1% negative impact on sales in the first half of 2025. Despite these challenges, the Zacks Consensus Estimate for 2025 earnings has remained stable, suggesting that the market views the company's core growth drivers as sufficient to offset the external pressures.

Key Decisions for Investors

• Investors should closely monitor the market adoption and initial sales figures for the newly approved over-the-counter CGM systems, Lingo and Libre Rio, as their success is a primary catalyst for future growth and market expansion.
• Given the identified headwinds, it is crucial to scrutinize upcoming earnings reports for management's commentary on margin pressure from input costs and the realized impact of foreign currency fluctuations on revenue and profitability.
• While Abbott's strong performance across its Diabetes Care and Established Pharmaceuticals divisions supports a bullish long-term outlook, the stock's recent 17.5% rally and Zacks #3 (Hold) rating suggest that new positions should be weighed against the persistent macroeconomic and currency risks.
• Consider the performance of better-ranked peers mentioned in the report, such as Masimo (MASI) and Cardinal Health (CAH), for comparative analysis or diversification within the broader healthcare sector.